Although the percentage of proliferating cells in spleens were lower in all treated mice, as compared with tumour/bearing untreated mice, the capacity of the CD8+ spleen cells to proliferate upon CD3/CD28 activation was not significantly impaired (Figure 7B). This evidence concerns the gene CD28 and neoplasm.